Clinical Trial Update: Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of vorinostat and isotretinoin in advanced kidney cancer (recurrent/stage III/IV renal cell cancer) has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-11-24